Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% Higher – Should You Buy?

by · The Markets Daily

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price shot up 21.5% on Monday . The stock traded as high as $8.15 and last traded at $8.01. 30,862,008 shares were traded during mid-day trading, an increase of 149% from the average session volume of 12,371,136 shares. The stock had previously closed at $6.59.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of recent analyst reports. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Finally, Jefferies Financial Group cut their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.25.

Check Out Our Latest Research Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average of $6.61 and a 200 day moving average of $7.31. The company has a market capitalization of $2.30 billion, a P/E ratio of -5.24 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period last year, the business posted ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% compared to the same quarter last year. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total value of $92,550.00. Following the completion of the sale, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at $8,500,754.52. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 134,235 shares of company stock valued at $895,538. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals in the third quarter worth about $25,000. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, KBC Group NV increased its stake in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read More